When an entrepreneur builds a product and fails, it’s always the wise step to go back to the drawing board. In the case of the CEO of Seattle Genetics, Clay Siegall, he doesn’t need to worry about failure yet, because his ideas have still been successful lately and have been so profitable that it’s hard to see why he’s not one of the most successful businessmen today.

The Recap of InterviewIn one of the most compelling interviews lately from Inspirery, it is revealed that Dr. Clay Siegall’s Seattle-based medical company that specializes in various targeted drugs for therapy is one of the most progressive and persistent medical technology companies in the market today. It is the mission of the company of Dr. Siegall to address the mortality issues in the society that have not been given the right answers yet. It is also the hope of his company to make sure that it goes through with its research unvexed and undiscouraged because the path to resistance is so great, that it might be just easy to give up.

When Dr. Siegall founded Seattle Genetics in 1998, he didn’t expect his company to be where it is right now. He didn’t expect that he could build strategic relationships and partners with big companies that can help him create more than 20 FDA-approved drugs. He didn’t expect that he could build networks with Bayer, Pfizer and many more big brands today that before were just dreams and wishes. Right now, these companies form the profit line of his company and have been the source of income of Dr. Siegall’s projects.

Professional Life of Dr. SiegallTruly, the remarkable success of Dr. Siegall comes from his professional track record. Aside from being the CEO of Seattle Genetics, he was also able to work for Alder Biopharmaceuticals, Mirna Therapeutics and Fred Hutchinson Cancer Research Center as a Board of Director and Board of Governor. His degree as a BS Zoology graduate at the University of Maryland could be the good reason why he has the backbone of the education that he has right now and why he is ahead of the curve in the professional competition.

Comments closed.